Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Free Cash Flow (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Free Cash Flow data on record, last reported at -$5.3 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 23.52% year-over-year to -$5.3 million; the TTM value through Dec 2025 reached -$19.4 million, up 17.82%, while the annual FY2025 figure was -$19.4 million, 17.82% up from the prior year.
  • Free Cash Flow reached -$5.3 million in Q4 2025 per LCTX's latest filing, down from -$3.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $21.9 million in Q1 2022 and bottomed at -$11.4 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$4.6 million, with a median of -$5.8 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: soared 393.99% in 2022, then plummeted 152.29% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$7.4 million in 2021, then dropped by 6.28% to -$7.9 million in 2022, then rose by 22.68% to -$6.1 million in 2023, then fell by 12.93% to -$6.9 million in 2024, then increased by 23.52% to -$5.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$5.3 million in Q4 2025, -$3.7 million in Q3 2025, and -$5.4 million in Q2 2025.